pomalidomide: Clinical Trials

53 trials of pomalidomide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

16 recruiting, 15 active not recruiting, 10 completed, 5 not yet recruiting. 53 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 353Recruiting 16, Active not recruiting 15, Completed 10, Not yet recruiting 5, Terminated 4, Unknown 2, Withdrawn 1
Phase 21Recruiting 1

Follow pomalidomide: new trials by email Literature Review of pomalidomide trials Research Report on pomalidomide

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.3002026-12-302026-11-12
Study of CM336+CM313 Combination Therapy in Patients With Relapsed or Refractory Multiple Myeloma
CM336, CM313, Daratumumab - Multiple Myeloma (MM)
Phase 3Not yet recruitingKeymed Biosciences Co.Ltd3202026-12-012026-11-02
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma
Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma
Phase 3Not yet recruitingAbbVie5202026-11-302026-07-27
Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma
InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Phase 3RecruitingCellCentric Ltd.4502026-08-012026-08-19
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Cevostamab, Pomalidomide, Dexamethasone - Multiple Myeloma
Phase 3RecruitingHoffmann-La Roche3802026-06-232026-11-10
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
BCD-248 + daratumumab, Daratumumab + pomalidomide + dexamethasone - Myeloma Multiple
Phase 3RecruitingBiocad3902026-06-152026-08-03
A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003
Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection) - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingInnovent Biologics (Suzhou) Co. Ltd.2552026-06-112026-09-17
Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
TQB2934 injection, Pomalidomide Capsule, Selinexor tablets - Multiple Myeloma
Phase 3Not yet recruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.2602026-06-012026-05-08
A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma
GR1803 injection, Daratumumab, Pomalidomide - Multiple Myeloma
Phase 3RecruitingGenrix (Shanghai) Biopharmaceutical Co., Ltd.3582026-03-092026-03-25
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AZD0120, Daratumumab, Carfilzomib - Relapsed Refractory Multiple Myeloma
Phase 3RecruitingAstraZeneca5082026-02-232026-09-29
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd) - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3RecruitingShandong New Time Pharmaceutical Co., LTD2612026-01-252026-05-12
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Linvoseltamab, Carfilzomib, Daratumumab - Relapsed and/or Refractory Multiple Myeloma (RRMM)
Phase 3RecruitingRegeneron Pharmaceuticals9152026-01-022026-11-04
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
QLS32015, Pomalidomide, Selinexor - Relapsed or Refractory Multiple Myeloma
Phase 3RecruitingQilu Pharmaceutical Co., Ltd.2282025-11-072026-05-22
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
BMS-986393, Cyclophosphamide, Fludarabine - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 3RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company4402025-03-122026-10-29
KPD Consolidation After ASCT in NDMM Patients
KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation - Multiple Myeloma, Newly Diagnosed
Phase 2 / Phase 3RecruitingPeking University People's Hospital2022025-03-012025-03-17
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
QL2109, Pomalidomide, Dexamethasone - Multiple Myeloma
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.2842025-01-012024-12-19
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine - Multiple Myeloma
Phase 3Active not recruitingKite, A Gilead Company4522024-08-232026-07-29
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
SG301 Injection, SG301 placebo, pomalidomide - Relapsed/Refractory Multiple Myeloma
Phase 3RecruitingHangzhou Sumgen Biotech Co., Ltd.3602024-06-142026-07-10
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
Etentamig, Carfilzomib, Pomalidomide - Multiple Myeloma
Phase 3Active not recruitingAbbVie4212024-05-192026-08-27
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Alnuctamab, Pomalidomide, Daratumumab - Multiple Myeloma
Phase 3WithdrawnCelgene2024-05-032024-05-31

Showing 20 of 53. Sign in to see all of them.

Conditions studied

Multiple Myeloma (48)  ·  Recurrence (14)  ·  Neoplasms, Plasma Cell (3)  ·  Neoplasms (2)  ·  Polycythemia Vera (1)  ·  Primary Myelofibrosis (1)

Sponsors

Celgene (8)  ·  Janssen Research & Development, LLC (6)  ·  Qilu Pharmaceutical Co., Ltd. (4)  ·  AbbVie (3)  ·  GlaxoSmithKline (3)  ·  Pfizer (2)  ·  Regeneron Pharmaceuticals (2)  ·  Sanofi (2)  ·  AstraZeneca (1)  ·  Biocad (1)  ·  Bristol-Myers Squibb (1)  ·  CellCentric Ltd. (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  European Myeloma Network B.V. (1)  ·  Fondazione EMN Italy Onlus (1)

Countries

Germany (33)  ·  Italy (33)  ·  Spain (33)  ·  France (31)  ·  United Kingdom (31)  ·  United States (31)  ·  China (28)  ·  Greece (26)  ·  Japan (26)  ·  Canada (25)  ·  Australia (24)  ·  Belgium (24)  ·  Poland (22)  ·  Czechia (21)  ·  Netherlands (21)

Top investigators

Aili He, MD, PhD (1)  ·  Amine Bensmaine, MD (1)  ·  Arina Zinkina (1)  ·  Baijun Fang, MD, PhD (1)  ·  Binghua Wang, MD, PhD (1)  ·  Congmeng Lin, MD, PhD (1)

Results publications

PMID 41627370, PMID 22081489, PMID 24007748, PMID 25425684, PMID 25629741, PMID 26149712, PMID 26160879, PMID 26250580, PMID 27081177, PMID 27102499, PMID 27173785, PMID 27267105, PMID 27773929, PMID 28193568, PMID 28642620, PMID 29396713, PMID 31097405, PMID 31327687, PMID 31982039, PMID 32586908, PMID 33086159, PMID 33839618, PMID 34087126, PMID 34800109, PMID 35032434, PMID 35641409, PMID 35876974, PMID 36108425, PMID 36762851, PMID 37272512, PMID 37355418, PMID 37793771, PMID 37793772, PMID 38112795, PMID 38299578, PMID 38426292, PMID 38651976, PMID 38828951, PMID 39110421, PMID 39197072, PMID 39234256, PMID 39756844, PMID 39865222, PMID 39938094, PMID 40459178, PMID 40613875, PMID 40763276, PMID 40768190, PMID 40958065, PMID 41193117

NIH funding

2023 (11), 2018 (3), 2015 (2), 2016 (1), 2019 (1), 2025 (1)